US priority review for Eisai cancer drug lenvatinib
Eisai has been boosted by news that regulators in the USA have agreed to a quicker review of its anticancer agent lenvatinib.
The US Food and Drug Administration has granted a priority review to Eisai’s New Drug Application for lenvatinib as a treatment for progressive radioiodine-refractory differentiated thyroid cancer. This means that the agency has assigned a Prescription Drug User Fee Act action date of April 14 next year, eight months after the NDA was submitted.
Read more at: http://www.pharmatimes.com/Article/14-10-15/US_priority_review_for_Eisai_cancer_drug_lenvatinib.aspx#ixzz3GH3iXiDU
SEE SYNTHESIS
Filed under: cancer, Priority review Tagged: CANCER, drug, eisai, Lenvatinib, Priority review, usfda
